Tag: Biotechnology Research

PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing
Australia

PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing

PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing to Accelerate US Expansion and Clinical Advancement of PREZIA™ Technology Platform CEO appointment and funding to support transformational US expansion, accelerate late-stage clinical development of lead asset, and strengthen R&D pipeline MELBOURNE, Australia & FORT WORTH, Texas – PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes … Continue reading PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing

Impact NewswireLeave a comment
Biogen and City Therapeutics Announce Strategic Research Collaboration
United States

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to develop select novel RNAi therapies. Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering … Continue reading Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Impact Newswire
Biotalys Appoints Luc Van fraeyenhoven as Chief Financial Officer
Europe

Biotalys Appoints Luc Van fraeyenhoven as Chief Financial Officer

Seasoned Financial Executive Will Lead Finance Operations as Biotalys Pushes Product Pipeline Toward Commercialization Ghent, BELGIUM – 26 May 2025, 07:00 CEST – Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the appointment of Luc Van fraeyenhoven as Chief Financial Officer (CFO). He succeeds Douglas Minder, who will pursue other career opportunities. Mr. Van fraeyenhoven will … Continue reading Biotalys Appoints Luc Van fraeyenhoven as Chief Financial Officer

Impact Newswire
Voyager Acquisition Corp. Announce Business Combination Agreement
Untied Kingdom

‍Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. · VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate (“ADC”) and Bispecific T-cell Engager (“TCE”) Candidates, with Strong and Differentiated Clinical Profiles · Company Pursuing Multiple Strategic Partnerships and Licensing … Continue reading ‍Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Impact Newswire
Aviceda Therapeutics Appoints Dr. Jeffrey Nau as Chief Executive Officer
United States

Aviceda Therapeutics Appoints Dr. Jeffrey Nau as Chief Executive Officer

Press Release – CAMBRIDGE, Mass. – Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Jeffrey Nau, Ph.D., M.M.S., as Chief Executive Officer (CEO), effective immediately. Dr. Nau will also join the Aviceda Board of Directors. Dr. Nau … Continue reading Aviceda Therapeutics Appoints Dr. Jeffrey Nau as Chief Executive Officer

Impact Newswire
Variational AI Announces Oversubscribed $5.5 Million
Global

Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery

New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies Press Release – February 20, 2025 – VANCOUVER, British Columbia – Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today announced the completion of its oversubscribed $US5.5 million Seed extension round. Enki™ empowers biopharmaceutical chemistry teams to efficiently discover and optimize novel hits and … Continue reading Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery

Impact Newswire
Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer
United States

Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer

Proven Pharmaceutical Executive Brings Over 30 Years of R&D Experience to Supercharge the Company’s Next Phase of Growth Seasoned Biotechnology Leader Mike Varney, Ph. D., Appointed as Lead Independent Director of the Board Press Release – SAN FRANCISCO, CALIFORNIA, FEBRUARY 18, 2025 – Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug discovery, today announced the appointment of Steve … Continue reading Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer

Impact Newswire
Syngenta and TraitSeq
Europe

Artificial intelligence is speeding up the development of the next generation of biostimulants

Syngenta Crop Protection and TraitSeq announce a pioneering collaboration which could help farmers transition to more sustainable practices. Press Release – January 09, 2025 – BASEL, Switzerland & NORWICH, England – Syngenta and the pioneering artificial intelligence (AI) company TraitSeq are combining forces to use the full power of AI for the development of innovative, high-performance biostimulants. Syngenta, a world leader in developing the next … Continue reading Artificial intelligence is speeding up the development of the next generation of biostimulants

Impact Newswire
IDRx
Untied Kingdom

GSK Enters Agreement to Acquire IDRx, Inc.

Press Release – January 13, 2025 – PLYMOUTH, Mass. – GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based … Continue reading GSK Enters Agreement to Acquire IDRx, Inc.

Impact Newswire